Juniper, OxSonics partner for cancer drug delivery platform
Juniper Pharma Services, a contract development and manufacturing organization (CDMO) subsidiary of Juniper Pharmaceuticals, has entered into a long-term collaboration with OxSonics to support the development, scale-up and GMP manufacturing of OxSonics' proprietary "sono-sensitive particles." OxSonics was established in July 2013 to develop and commercialize therapeutic ultrasound advancements invented at the University of Oxford's Institute of Biomedical Engineering.
The collaboration will see the CDMO support the Oxford-based company develop these injectable particles, which when used in conjunction with new generation ultrasound devices can be applied to a range of therapeutic applications including an oncological drug delivery platform called SonoTran. SonoTran is designed to enhance the delivery of anti-cancer drugs deep into and throughout solid tumors.
With an established track record of helping specialty pharmaceutical companies and emerging biotechs develop new products and platforms, Juniper Pharma Services is able to mitigate risk and optimize formulation performance through its science-led approach to projects.
Formerly known as Molecular Profiles, Juniper Pharma Services unveiled its new identity earlier this year to coincide with the rebranding of its Boston-based parent company, Juniper Pharmaceuticals.
Upcoming Events
-
21Oct